ShermanRAShermanCJParkerL. Chronic phantom and stump pain among American veterans: Results of a survey. Pain1994;18: 83–95.
4.
DavisRW. Phantom sensation, phantom pain, and stump pain. Arch Phys Med Rehabil1993;74: 79–90.
5.
JensenTSKrebsBNielsenJRasmussenP. Immediate and long term phantom pain in amputees: Incidence, clinical characteristics, and relationship to pre-amputation limb pain. Pain1985;21: 267–78.
6.
IaconoRPLinfordJSandykR. Pain management after lower extremity amputation. Neurosurgery1987;20: 496–500.
7.
RibbersGMulderTRijkenR. The phantom phenomenon: A critical review. Int J Rehabil Res1989;12: 175–86.
8.
ShermanRAArenaJGShermanCJErnstJL. The mystery of phantom pain: Growing evidence for psychophysiological mechanisms. Biofeedback and Self-Regulation1989;14: 267–81.
9.
PostoneN. Phantom limb pain: A review. Int J Psychiatry Med1987;17: 57–70.
10.
CanaveroS. Dynamic reverberation. A united mechanism for central and phantom pain. Med Hypotheses1994;42: 203–7.
11.
BachSNorengMFTjelldenNU. Phantom limb pain in amputees during the first 12 months following limb amputation, after preoperative lumbar epidural blockade. Pain1988;33: 297–301.
12.
NikolajsenLIlkajerSKronerKChristensenJHJensenTS. The influence of preamputation pain on postamputation stump and phantom pain. Pain1997;72: 393–405.
13.
UrbanBJFranceRDSteinbergerEKScottDLMaltbieAA. Long term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain1986;24: 191–6.
14.
ShermanRATippensJK. Suggested guidelines for treatment of phantom limb pain. Orthopedics1982;5: 1595–600.
15.
Power-SmithPTurkingtonD. Fluoxetine in phantom limb pain. Br J Psychiatry1993;163: 105–6.
16.
DavisRW. Successful treatment for phantom pain. Orthopedics1993;16: 691–5.
17.
BragaPC. Calcitonin and its antinociceptive activity: Animal and human investigations 1975–92. Agents Actions1994;41: 121–31.
18.
SzantoJAdyNJozsefS. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology1992;49: 180–2.
19.
CombeBCohenCAubinF. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int1997;61: 10–5.